Table 2 Pretreatment HIV drug resistance mutations among HIV-infected individuals with drug resistance

Total

Non-nucleoside reverse transcriptase inhibitors (NNRTIs, any)

K103N/S/T,36 (2.1)

V179D/E/T,28 (1.6)

E138AA/K/G/Q,18 (1.1)

V106M,9 (0.5)

G190A/S,6 (0.4)

Y188L/C/F,6 (0.4)

Efavirenz (EFV)^a

K101E,4 (0.2)

Nevirapine (NVP)^a

Y181C,3 (0.2)

H221Y,3 (0.2)

A98G,2 (0.1)

F227L,1 (0.06)

L100I,1 (0.06)

P225,1 (0.06)

Nucleoside reverse transcriptase inhibitors (NRTIs, any)

K65R,9 (0.5)

D67N,8 (0.5)

M184I/V,7 (0.4)

Emtricitabine (FTC)

T215D/I/S,7 (0.4)

Lamivudine (3TC)^a

K70E/R/T,5 (0.3)

Abacavir (ABC)^a

L210W,4 (0.2)

Didanosine (DDI)^a

K219R,2 (0.1)

Stavudine (D4T)^a

L74LI,2 (0.1)

Tenofovir (TDF)^a

M41L,2 (0.1)

Azidothymidine (AZT)^a

T69D,2 (0.1)

Y115F,2 (0.1)

A62V,1 (0.06)

V75I,1 (0.06)

Protease inhibitors (PIs, any)

I47V,3 (0.2)

I50V,2 (0.1)

Atazanavir (ATV)

I54V,2 (0.1)

Darunavir (DRV)

V82A/FI/L,2 (0.1)

Lopinavir (LPV)^a

I84V,1 (0.06)

L90M,1 (0.06)

M46I/L,1 (0.06)

Multi-drug resistance to NNRTI and NRTI

Multi-drug resistance to NNRTI, NRTI and PI